Determinants of Long‐Term Outcomes and Costs in the Management of Critical Limb Ischemia: A Population‐Based Cohort Study
Jihad A. Mustapha, MD; Barry T. Katzen, MD; Richard F. Neville, MD; Robert A. Lookstein, MD; Thomas Zeller, MD; Larry E. Miller, PhD; and Michael R. Jaff, DO
The optimal treatment for critical limb ischemia remains controversial owing to conflicting conclusions from previous studies.
We obtained administrative claims on Medicare beneficiaries with initial critical limb ischemia diagnosis in 2011. Clinical outcomes and healthcare costs over 4 years were estimated among all patients and by first treatment (endovascular revascularization, surgical revascularization, or major amputation) in unmatched and propensity‐score–matched samples.